Select your country

18.11.2014
STADA and mAbxience enter into negotiations over Adalimumab biosimilar
STADA and mAbxience enter into negotiations over Adalimumab biosimilar

STADA and mAbxience enter into negotiations over Adalimumab biosimilar

Read more

13.11.2014
STADA: Good result despite challenging framework conditions – Group sales rise by 4 percent – significant increase of adjusted EBITDA by 12 percent and adjusted net income by 36 percent – outlook for 2014 confirmed
16.10.2014
New STADA initiative investigates daily approach to health
New STADA initiative investigates daily approach to health

New STADA initiative investigates daily approach to health

Read more

13.10.2014
STADA in-licenses teriparatide and further expands biosimilar portfolio
STADA in-licenses teriparatide and further expands biosimilar portfolio

STADA in-licenses teriparatide and further expands biosimilar portfolio

Read more

10.10.2014
STADA plans to hand German logistics business over to a globally active and well-known logistics company
STADA plans to hand German logistics business over to a globally active and well-known logistics company

STADA plans to hand German logistics business over to a globally active and well-known logistics company

Read more

16.09.2014
STADA expands branded product strategy
STADA expands branded product strategy

STADA expands branded product strategy

Read more

07.08.2014
STADA: Solid result in difficult market environment – Group sales increase by 4 percent – adjusted key earnings figures substantially higher than previous year – reported net income approximately at prior-year level
07.08.2014
Interview with Chief Financial Officer Helmut Kraft on the occasion of the half-year results
Interview with Chief Financial Officer Helmut Kraft on the occasion of the half-year results

Interview with Chief Financial Officer Helmut Kraft on the occasion of the half-year results

Read more

30.06.2014
STADA strengthens its branded product portfolio by purchasing the Flexitol® rights for UK and Ireland – a dermatological range in the area of hand and foot care
STADA strengthens its branded product portfolio by purchasing the Flexitol® rights for UK and Ireland – a dermatological range in the area of hand and foot care

STADA strengthens its branded product portfolio by purchasing the Flexitol® rights for UK and Ireland – a dermatological range in the area o…

Read more

04.06.2014
STADA Executive Board shows satisfaction with financial year 2013 at Annual General Meeting and adheres to outlook for 2014
STADA Executive Board shows satisfaction with financial year 2013 at Annual General Meeting and adheres to outlook for 2014

STADA Executive Board shows satisfaction with financial year 2013 at Annual General Meeting and adheres to outlook for 2014

Read more

04.06.2014
Three questions for Chairman of the Executive Board Hartmut Retzlaff
Three questions for Chairman of the Executive Board Hartmut Retzlaff

Three questions for Chairman of the Executive Board Hartmut Retzlaff

Read more

20.05.2014
STADA subsidiary supports victims of Balkan flood
STADA subsidiary supports victims of Balkan flood

STADA subsidiary supports victims of Balkan flood

Read more

08.05.2014
STADA with positive development in the first quarter of 2014 – Group sales rise by 7 percent – reported EBITDA and reported net income slightly over previous year level despite CIS crisis
STADA with positive development in the first quarter of 2014 – Group sales rise by 7 percent – reported EBITDA and reported net income slightly over previous year level despite CIS crisis

STADA with positive development in the first quarter of 2014 – Group sales rise by 7 percent – reported EBITDA and reported net income sligh…

Read more

24.03.2014
STADA: Successful financial year 2013 – Adjusted EBITDA reaches new record high – Dividend to increase by 32 percent – 2014 outlook adjusted
STADA: Successful financial year 2013 – Adjusted EBITDA reaches new record high – Dividend to increase by 32 percent – 2014 outlook adjusted

STADA: Successful financial year 2013 – Adjusted EBITDA reaches new record high – Dividend to increase by 32 percent – 2014 outlook adjusted…

Read more

03.03.2014
STADA:  Preliminary figures show successful financial year 2013 – Dividend to increase by 32 percent – Outlook for 2014 confirmed
STADA: Preliminary figures show successful financial year 2013 – Dividend to increase by 32 percent – Outlook for 2014 confirmed

STADA: Preliminary figures show successful financial year 2013 – Dividend to increase by 32 percent – Outlook for 2014 confirmed

Read more

28.02.2014
STADA: Successfully concluded purchase of the Russian branded product portfolio Aqualor® for the self-medication of sinusitis and sore throat
STADA: Successfully concluded purchase of the Russian branded product portfolio Aqualor® for the self-medication of sinusitis and sore throat

STADA: Successfully concluded purchase of the Russian branded product portfolio Aqualor® for the self-medication of sinusitis and sore throa…

Read more

14.02.2014
STADA: Local insolvency administrator files lawsuit against a subsidiary of STADA Arzneimittel AG
STADA: Local insolvency administrator files lawsuit against a subsidiary of STADA Arzneimittel AG

STADA: Local insolvency administrator files lawsuit against a subsidiary of STADA Arzneimittel AG

Read more

22.01.2014
STADA exceeds two-billion-euro mark in sales
STADA exceeds two-billion-euro mark in sales

STADA exceeds two-billion-euro mark in sales

Read more

17.01.2014
STADA: Executive Board contract of Chief Financial Officer Helmut Kraft extended by four years
STADA: Executive Board contract of Chief Financial Officer Helmut Kraft extended by four years

STADA: Executive Board contract of Chief Financial Officer Helmut Kraft extended by four years

Read more